Alterations in the endocannabinoid system in the rat valproic acid model of autism

Behavioural Brain Research

Volumn 249, Issue , 2013, Pages 124-132

  Kerr, D M ^a   Downey, L ^a   Conboy, M ^a   Finn, D P ^a   Roche, M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Anandamide; Oleoylethanolamide; Palmitoylethanolamide; PPAR; Social interaction; Valproate

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL PALMITOYLTRANSFERASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MESSENGER RNA; N OLEOYLETHANOLAMINE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXPERIMENTAL TEST; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HOT PLATE TEST; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SOCIABILITY TEST; SOCIAL BEHAVIOR; TANDEM MASS SPECTROMETRY; TISSUE LEVEL;

AMIDOHYDROLASES; ANIMALS; AUTISTIC DISORDER; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; MALE; MONOACYLGLYCEROL LIPASES; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SOCIAL BEHAVIOR; VALPROIC ACID;

EID: 84878136965     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.04.043     Document Type: Article

References (53)

1. Williams P.G., Hersh J.H. A male with fetal valproate syndrome and autism. Developmental Medicine and Child Neurology 1997, 39:632-634.
2. Williams G., King J., Cunningham M., Stephan M., Kerr B., Hersh J.H. Fetal valproate syndrome and autism: additional evidence of an association. Developmental Medicine and Child Neurology 2001, 43:202-206.
3. Christianson A.L., Chesler N., Kromberg J.G. Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. Developmental Medicine and Child Neurology 1994, 36:361-369.
4. Schneider T., Labuz D., Przewlocki R. Nociceptive changes in rats after prenatal exposure to valproic acid. Polish Journal of Pharmacology 2001, 53:531-534.
5. Schneider T., Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
6. Schneider T., Ziolkowska B., Gieryk A., Tyminska A., Przewlocki R. Prenatal exposure to valproic acid disturbs the enkephalinergic system functioning, basal hedonic tone, and emotional responses in an animal model of autism. Psychopharmacology 2007, 193:547-555.
7. Markram K., Rinaldi T., La Mendola D., Sandi C., Markram H. Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 2008, 33:901-912.
8. Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicology and Teratology 2000, 22:319-324.
9. Rodier P.M., Ingram J.L., Tisdale B., Croog V.J. Linking etiologies in humans and animal models: studies of autism. Reproductive Toxicology 1997, 11:417-422.
10. Sui L., Chen M. Prenatal exposure to valproic acid enhances synaptic plasticity in the medial prefrontal cortex and fear memories. Brain Research Bulletin 2012, 87:556-563.
11. Rinaldi T., Perrodin C., Markram H. Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic acid animal model of autism. Frontiers in Neural Circuits 2008, 2:1-7.
12. Kim K.C., Kim P., Go H.S., Choi C.S., Park J.H., Kim H.J., et al. Male-specific alteration in excitatory postsynaptic development and social interaction in prenatal valproic acid exposure model of autism spectrum disorder. Journal of Neurochemistry 2013, 124:832-843.
13. Dufour-Rainfray D., Vourc'h P., Le Guisquet A.M., Garreau L., Ternant D., Bodard S., et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neuroscience Letters 2010, 470:55-59.
14. Schneider T., Roman A., Basta-Kaim A., Kubera M., Budziszewska B., Schneider K., et al. Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 2008, 33:728-740.
15. Lutz B. Endocannabinoid signals in the control of emotion. Current Opinion in Pharmacology 2009, 9:46-52.
16. Viveros M.P., Marco E.M., Llorente R., Lopez-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plasticity 2007, 2007:1-12.
17. Hogestatt E.D., Jonsson B.A., Ermund A., Andersson D.A., Bjork H., Alexander J.P., et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. The Journal of Biological Chemistry 2005, 280:31405-31412.
18. Schultz S.T. Can autism be triggered by acetaminophen activation of the endocannabinoid system?. Acta Neurobiologiae Experimentalis (Warsaw) 2010, 70:227-231.
19. Chakrabarti B., Kent L., Suckling J., Bullmore E., Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. European Journal of Neuroscience 2006, 23:1944-1948.
20. Chakrabarti B., Baron-Cohen S. Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces. Molecular Autism 2011, 2:1-7.
21. Trezza V., Damsteegt R., Manduca A., Petrosino S., Van Kerkhof L.W., Pasterkamp R.J., et al. Endocannabinoids in amygdala and nucleus accumbens mediate social play reward in adolescent rats. Journal of Neuroscience 2012, 32:14899-14908.
22. Marco E.M., Rapino C., Caprioli A., Borsini F., Maccarrone M., Laviola G. Social encounter with a novel partner in adolescent rats: activation of the central endocannabinoid system. Behavioral Brain Research 2011, 220:140-145.
23. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochemical Journal 1998, 331(Pt 1):15-19.
24. Trezza V., Vanderschuren L.J. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology 2008, 197:217-227.
25. Umathe S.N., Manna S.S., Utturwar K.S., Jain N.S. Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Progress in Neuropsychopharmacology and Biological Psychiatry 2009, 33:1191-1199.
26. Gould G.G., Seillier A., Weiss G., Giuffrida A., Burke T.F., Hensler J.G., et al. Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Progress in Neuropsychopharmacology and Biological Psychiatry 2012, 38:260-269.
27. Meyza, K.Z., Defensor, E.B., Jensen, A.L., Corley, M.J., Pearson, B.L., Pobbe, R.L., et al. The BTBR T(+)tf/J mouse model for autism spectrum disorders-in search of biomarkers. Behavioral Brain Research, , in press. doi:10.1016/j.bbr.2012.07.021.
28. Onaivi E.S., Benno R., Halpern T., Mehanovic M., Schanz N., Sanders C., et al. Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Current Neuropharmacology 2011, 9:209-214.
29. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proceedings of the National Academy of Sciences of United States of America 2002, 99:10819-10824.
30. Gao Y., Vasilyev D.V., Goncalves M.B., Howell F.V., Hobbs C., Reisenberg M., et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. Journal of Neuroscience 2010, 30:2017-2024.
31. Maccarrone M., Rossi S., Bari M., De Chiara V., Rapino C., Musella A., et al. Abnormal mGlu 5 receptor/endocannabinoid coupling in mice lacking FMRP and BC1 RNA. Neuropsychopharmacology 2010, 35:1500-1509.
32. Jung K.M., Sepers M., Henstridge C.M., Lassalle O., Neuhofer D., Martin H., et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nature Communications 2012, 3:1-11.
33. Sun Y., Alexander S.P., Kendall D.A., Bennett A.J. Cannabinoids and PPARalpha signalling. Biochemical Society Transactions 2006, 34:1095-1097.
34. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology 2007, 152:1092-1101.
35. Sandhya T., Sowjanya J., Veeresh B. Bacopa monniera (L.) Wettst ameliorates behavioral alterations and oxidative markers in sodium valproate induced autism in rats. Neurochemical Research 2012, 37:1121-1131.
36. Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Mental Retardation and Developmental Disabilities Research Reviews 2004, 10:248-258.
37. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., et al. Automated apparatus for quantitation of social approach behaviors in mice. Genes, Brain and Behavior 2004, 3:303-314.
38. Kerr D.M., Burke N.N., Ford G.K., Connor T.J., Harhen B., Egan L.J., et al. Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 2012, 1:53-63.
39. Olango W.M., Roche M., Ford G.K., Harhen B., Finn D.P. The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone. British Journal of Pharmacology 2012, 165:2549-2560.
40. Kerr, D.M., Harhan, B., Okine, B.N., Egan, L.J., Finn, D.P., Roche, M. The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. British Journal of Pharmacology, , in press. doi:10.1111/j.1476-5381.2012.02237.
41. Ford G.K., Kieran S., Dolan K., Harhen B., Finn D.P. A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. Pain 2011, 152:2495-2504.
42. Cable J.C., Tan G.D., Alexander S.P., O'Sullivan S.E. The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans. Lipids in Health and Disease 2011, 10:129.
43. Kim K.C., Kim P., Go H.S., Choi C.S., Yang S.I., Cheong J.H., et al. The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. Toxicology Letters 2011, 201:137-142.
44. Kim P., Park J.H., Kwon K.J., Kim K.C., Kim H.J., Lee J.M., et al. Effects of Korean red ginseng extracts on neural tube defects and impairment of social interaction induced by prenatal exposure to valproic acid. Food and Chemical Toxicology 2013, 51:288-296.
45. Militerni R., Puglisi-Allegra S., Pascucci T., Bravaccio C., Falco C., Fico C. Pain reactivity in children with autistic disorder. Journal of the Intellectual Disability Research 2000, 44:394-395.
46. Tordjman S., Anderson G.M., Botbol M., Brailly-Tabard S., Perez-Diaz F., Graignic R., et al. Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder. PLoS ONE 2009, 4:e5289.
47. Zhang Y., Sun Y., Wang F., Wang Z., Peng Y., Li R. Downregulating the canonical Wnt/beta-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress. Neurochemical Research 2012, 37:1409-1419.
48. Cassano T., Gaetani S., Macheda T., Laconca L., Romano A., Morgese M.G., et al. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice. Psychopharmacology 2011, 214:465-476.
49. Trezza V., Vanderschuren L.J. Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. Journal of Pharmacology and Experimental Therapeutics 2009, 328:343-350.
50. Zenko M., Zhu Y., Dremencov E., Ren W., Xu L., Zhang X. Requirement for the endocannabinoid system in social interaction impairment induced by coactivation of dopamine D1 and D2 receptors in the piriform cortex. Journal of Neuroscience Research 2011, 89:1245-1258.
51. Egerton A., Allison C., Brett R.R., Pratt J.A. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neuroscience and Biobehavioral Reviews 2006, 30:680-695.
52. Denner L.A., Rodriguez-Rivera J., Haidacher S.J., Jahrling J.B., Carmical J.R., Hernandez C.M., et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. The Journal of Neuroscience 2012, 32:16725-16735.
53. Campolongo P., Roozendaal B., Trezza V., Cuomo V., Astarita G., Fu J., et al. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation. Proceedings of the National Academy of Sciences of United States of America 2009, 106:8027-8031.